Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences (SLDB) has announced the granting of 11,950 restricted stock units (RSUs) to a newly hired employee. The RSUs are structured with a four-year vesting schedule, with 25% of the units vesting annually on each grant date anniversary. The equity award, issued under the Company's 2024 Inducement Stock Incentive Plan, serves as an employment inducement and complies with Nasdaq Listing Rule 5635(c)(4). The vesting is contingent upon the employee's continued service with the company through each vesting date.
Solid Biosciences (SLDB) ha annunciato l'assegnazione di 11.950 unità di azioni riservate (RSU) a un nuovo dipendente. Le RSU sono strutturate con un piano di maturazione di quattro anni, con il 25% delle unità che matura annualmente in corrispondenza dell'anniversario della data di assegnazione. Il premio azionario, emesso sotto il Piano di Incentivazione Azionaria per Induzione 2024 della società, funge da incentivo all'impiego e rispetta la Regola di Quotazione Nasdaq 5635(c)(4). La maturazione è subordinata al continuo servizio del dipendente con la società fino a ciascuna data di maturazione.
Solid Biosciences (SLDB) ha anunciado la concesión de 11,950 unidades de acciones restringidas (RSUs) a un nuevo empleado. Las RSUs están estructuradas con un calendario de adquisición de cuatro años, con el 25% de las unidades adquiriéndose anualmente en cada aniversario de la fecha de concesión. La concesión de acciones, emitida bajo el Plan de Incentivos de Acciones por Inducción 2024 de la compañía, sirve como un incentivo para el empleo y cumple con la Regla de Cotización de Nasdaq 5635(c)(4). La adquisición está condicionada a la continuidad del servicio del empleado con la empresa hasta cada fecha de adquisición.
솔리드 바이오사이언스(SLDB)는 새로 채용된 직원에게 11,950개의 제한 주식 단위(RSU)를 부여한다고 발표했습니다. RSU는 4년의 베스팅 일정으로 구성되어 있으며, 매년 부여일 기념일에 25%의 유닛이 베스팅됩니다. 이 주식 보상은 회사의 2024 유인 주식 인센티브 계획에 따라 발행되며, 고용 유인을 제공하고 Nasdaq 상장 규칙 5635(c)(4)를 준수합니다. 베스팅은 직원이 각 베스팅 날짜까지 회사에 계속 근무하는 것을 조건으로 합니다.
Solid Biosciences (SLDB) a annoncé l'octroi de 11 950 unités d'actions restreintes (RSU) à un nouvel employé. Les RSU sont structurées avec un calendrier d'acquisition de quatre ans, 25 % des unités étant acquises chaque année à la date anniversaire de l'octroi. La récompense en actions, émise dans le cadre du Plan d'Incitation aux Actions 2024 de l'entreprise, sert d'incitation à l'emploi et est conforme à la Règle de Cotation Nasdaq 5635(c)(4). L'acquisition est conditionnée à la poursuite du service de l'employé au sein de l'entreprise jusqu'à chaque date d'acquisition.
Solid Biosciences (SLDB) hat die Gewährung von 11.950 beschränkten Aktieneinheiten (RSUs) an einen neu eingestellten Mitarbeiter bekannt gegeben. Die RSUs sind mit einem vierjährigen Vesting-Plan strukturiert, wobei 25% der Einheiten jährlich am Jahrestag des Zuteilungsdatums vesten. Die Aktienauszeichnung, die im Rahmen des 2024 Inducement Stock Incentive Plans des Unternehmens ausgegeben wird, dient als Anreiz für die Beschäftigung und entspricht der Nasdaq-Listing-Regel 5635(c)(4). Das Vesting ist davon abhängig, dass der Mitarbeiter bis zu jedem Vesting-Datum weiterhin im Unternehmen tätig ist.
- None.
- None.
CHARLESTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,950 restricted stock units (“RSUs”) to one newly hired employee.
The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the employee’s continued service with the Company through each applicable vesting date.
This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich’s ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy, BAG3-mediated dilated cardiomyopathy, and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
What is the vesting schedule for the new RSUs granted by Solid Biosciences (SLDB)?
How many restricted stock units (RSUs) did Solid Biosciences grant in March 2025?
Under which plan were the SLDB inducement grants issued?
What is the purpose of SLDB's March 2025 RSU grant?
